References
- Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18(7):1028–1040.
- Dattagupta A, Immaneni S. ST2: current status. Indian Heart J. 2018;70:S96–S101.
- Pascual-Figal DA, Januzzi JL. The biology of ST2: the international ST2 consensus panel. Am J Cardiol. 2015;115(7 Suppl.):3B–7B.
- Aimo A, Migliorini P, Vergaro G, et al. The IL-33/ST2 pathway, inflammation and atherosclerosis: trigger and target? Int J Cardiol. 2018;267:188–192.
- Pusceddu I, Dieplinger B, Mueller T. ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans. Clin Chim Acta. 2019;495:493–500.
- Kotsiou OS, Gourgoulianis KI, Zarogiannis SG. IL-33/ST2 axis in organ fibrosis. Front Immunol. 2018;9:2432.
- Mueller T, Jaffe AS. Soluble ST2 – analytical considerations. Am J Cardiol. 2015;115(7):8B–21B.
- Lin YH, Zhang RC, Hou LB, et al. Distribution and clinical association of plasma soluble ST2 during the development of type 2 diabetes. Diabetes Res Clin Pract. 2016;118:140–145.
- Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med. 1998;15(7):539–553.
- Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7):2402–2410.
- Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–854.
- Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198.
- Vasunta R-L, Kesäniemi YA, Ylitalo A, et al. Nondipping patter and carotid atherosclerosis in a middle-aged population: OPERA study. Am J Hypertens. 2012;25(1):60–66.
- Rantala AO, Kauma H, Lilja M, et al. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med. 1999;245(2):163–174.
- Leinonen T, Kesäniemi YA, Hedberg P, et al. Serum ghrelin and prediction of metabolic parameters in over 20-year follow-up. Peptides. 2016;76:51–56.
- Pascual-Figal DA, Lax A, Perez-Martinez MT, et al. Clinical relevance of sST2 in cardiac diseases. Clin Chem Lab Med. 2016;54(1):29–35.
- Fousteris E, Melidonis A, Panoutsopoulos G, et al. Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. Cardiovasc Diabetol. 2011;10(1):101.
- Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922.
- Bai F, Ba F, You Y, et al. Decreased ST2 expression is associated with gastric cancer progression and pathogenesis. Oncol Lett. 2019;17:5761–5767.
- Larsen KM, Minaya MK, Vaish V, et al. The role of IL-33/ST2 pathway in tumorigenesis. Int J Mol Sci. 2018;19(9):2676.
- De la Fuente M, MacDonald TT, Hermoso MM. The IL-33/ST2 axis: role in health and disease. Cytokine Growth Factor Rev. 2015;26(6):615–623.
- Roberts R, Knopman DS. Classification and epidemiology of MCI. Clin Geriatr Med. 2013;29(4):753–772.
- Xiong Z, Thangavel R, Kempuraj D, et al. Alzheimer's disease: evidence for the expression of interleukin-33 and its receptor ST2 in the brain. J Alzheimers Dis. 2014;40(2):297–308.
- Moheet A, Mangia S, Seaquist ER. Impact of diabetes on cognitive function and brain structure. Ann N Y Acad Sci. 2015;1353:60–71.
- Vieira MNN, Lima-Filho RAS, De Felice FG. Connecting Alzheimer's disease to diabetes: underlying mechanisms and potential therapeutic targets. Neuropharmacology. 2018;136(Pt B):160–171.
- Chen LQ, de Lemos JA, Das SR, et al. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. Clin Chem. 2013;59(3):536–546.